Cargando…
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence
BACKGROUND: Efalizumab is a humanised recombinant monoclonal IgG1 antibody for the treatment of moderate-to-severe plaque psoriasis. When treatment discontinuation is necessary, however, some patients may experience inflammatory recurrence of the disease, which can progress to rebound if untreated....
Autores principales: | Papp, Kim A, Toth, Darryl, Rosoph, Les |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636659/ https://www.ncbi.nlm.nih.gov/pubmed/17067371 http://dx.doi.org/10.1186/1471-5945-6-9 |
Ejemplares similares
-
Evaluation of efalizumab using safe psoriasis control
por: Papp, Kim A, et al.
Publicado: (2006) -
Efalizumab in the treatment of psoriasis
por: Boehncke, Wolf-Henning
Publicado: (2007) -
Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series
por: Lowes, Michelle A, et al.
Publicado: (2007) -
Efalizumab-induced severe thrombocytopenia can be resolved
por: Prignano, Francesca, et al.
Publicado: (2008) -
Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results
por: Stengel, Fernando M, et al.
Publicado: (2009)